OMC
JBIO

OUP Management Company’s Jade Biosciences JBIO Stock Holding History

OUP Management Company’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$8.19M Hold
17,250
– – 18.43% 2
2023
Q2 		$10.4M Hold
17,250
– – 17.66% 3
2023
Q1 		$12.2M Hold
17,250
– – 24.3% 1
2022
Q4 		$17.7M Hold
17,250
– – 28.88% 1
2022
Q3 		$10M Hold
17,250
– – 15.59% 4
2022
Q2 		$9.44M Hold
17,250
– – 12.99% 3
2022
Q1 		$11.1M Hold
17,250
– – 8.43% 4
2021
Q4 		$7.12M Buy
+17,250
New +$8.73M 3.21% 10

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

OUP Management Company's JBIO Position: Q3 2023 in Review

OUP Management Company held its Jade Biosciences (JBIO) position steady in Q3 2023 at 17,250 shares worth $8.19M. The position accounts for 18.43% of the portfolio, ranked #2.

OUP Management Company first reported a position in JBIO in Q4 2021 and has held it in 8 quarters since. The position peaked at $17.7M in Q4 2022. 58 funds tracked by Wall St. Rank hold JBIO as of Q3 2023.

  • OUP Management Company held 17,250 shares of Jade Biosciences worth $8.19M as of Q3 2023.
  • OUP Management Company left its Jade Biosciences share count unchanged in Q3 2023.
  • Jade Biosciences made up 18.43% of OUP Management Company's portfolio in Q3 2023, its #2 holding.
  • OUP Management Company first reported a position in Jade Biosciences in Q4 2021 and has held it in 8 quarters since.
  • OUP Management Company's Jade Biosciences position peaked at $17.7M in Q4 2022.
  • 58 funds tracked by Wall St. Rank held Jade Biosciences as of Q3 2023.

Based on OUP Management Company's 13F filing for Q3 2023, filed 9 Nov 2023.